New industry ranking suggests longevity has moved beyond fringe science, with the surrounding infrastructure growing as fast as the science.
There was a time (not that long ago) when talking seriously about longevity biotech could clear a room. The industry carried baggage: billionaire biohackers, cryogenic fantasies, narratives about “living forever”. For many outside the industry, longevity felt less like a credible healthcare category until it tended to reveal itself gradually. First comes curiosity, then capital, then infrastructure. Eventually, if momentum holds, legitimacy.
The newly released Unfiltered Longevity 100 feels like one of those legitimacy moments. Published by London-based media brand Unfiltered as part of the The Longevity Money Map, the report ranks 100 people shaping the longevity industry in 2026 across science, investment, entrepreneurship and influence. The list scores figures based on capital power, scientific credibility, strategic influence, original impact and public profile – like an attempt to map where real gravity in the sector now sits.
At the top are heavyweight names already familiar to biotech and AI watchers: Altos Labs CEO Hal Barron, Hevolution Foundation CEO Mehmood Khan, investor Vinod Khosla, DeepMind CEO Demis Hassabis and stem cell pioneer Shinya Yamanaka.
But perhaps one of the more quietly significant inclusions sits further down the list. Phil Newman lands at #99 for what he has built through Longevity.Technology and The Longevity Show, platforms that have spent years documenting, questioning and translating a rapidly evolving industry long before longevity became a fashionable boardroom conversation.
The industry is getting harder to ignore
According to the report, longevity investment rebounded to $8.49 billion in 2024 after collapsing by more than 60% in 2023. However, what stands out is not simply the recovery itself; it is how the money is moving.
The easy enthusiasm appears to be fading. Investors are concentrating capital into fewer, higher-conviction bets. In practical terms, the industry is becoming more selective and more disciplined. That is often what happens when a sector matures.
For years, longevity startups could raise money largely on ambition: reverse aging, extend lifespan, reprogram cells. Today, the conversation is shifting toward mechanisms, clinical pathways and measurable outcomes. Investors want evidence. Regulators want evidence. Increasingly, the public does as well.
Newman believes that shift marks an important turning point for the sector.
“Longevity is moving beyond its ‘hype cycle’ and into a more evidence-led phase, where serious capital, rigorous clinical data and emerging regulatory pathways are starting to dominate the conversation,” he told us. “There is still a worrying gap between what people read on social media and where the real data exists, but this is changing.”
Some of that evidence is beginning to emerge.
The report highlights that the first human trial of partial cellular reprogramming is now beginning to enroll patients, a milestone that would have sounded almost like fiction even a decade ago.
The science itself is undeniably complex, but the underlying idea is intuitive. Aging can be thought of like software accumulating glitches over time. Cells lose information, tissues become less resilient and repair systems start breaking down. Partial cellular reprogramming aims to reset some of those cellular instructions without wiping the system entirely clean.
Whether it succeeds remains an open question. Many approaches in longevity biotech will fail. Some probably should fail. Nonetheless, failure inside a serious scientific field looks very different from failure inside hype.
“Most power lists are about attention. This one is about money, science and execution,” said Jon Lipsey, Cofounder and Content Director of Unfiltered. “We ranked the people building the category and deciding where it goes next.”
Jon Lipsey is the Cofounder and Content Director of Unfiltered
It is a telling line that the industry no longer revolves purely around aspiration; it revolves around who can actually build.
Why DLT reflects longevity’s next phase
As longevity grows more crowded, another challenge is emerging alongside the science: information overload.
New companies appear almost weekly. Funding rounds blur together. Scientific claims move faster than public understanding. Investors, founders and operators increasingly face the same problem: how do you separate signal from noise in a field evolving this quickly?
That is where platforms like Decoding Longevity Trends (DLT) come in. Built by Longevity.Technology, DLT functions as a specialist intelligence platform for the longevity biotech sector. At its core, it is designed to help users search companies, monitor assets, track clinical progress and generate strategic insights across the industry.
Newman says recognition in the Unfiltered Longevity 100 reflects a broader shift in how intelligence platforms are now viewed inside the industry.
“Being included in the Unfiltered Longevity 100 signals that platforms like Longevity.Technology and our AI data system DLT are no longer just commentators, but part of the decision-making infrastructure that investors, entrepreneurs and clinicians now rely on to navigate this sector.”
Every emerging industry eventually builds its own infrastructure layer. AI developed specialized compute platforms and data ecosystems. Fintech built real-time payment rails and compliance systems. Longevity is now building its own intelligence architecture: tools capable of tracking the increasingly complex web of companies, therapeutics, patents, partnerships and investment activity shaping the field.
DLT’s workflows – automated alerts, live dashboards, advanced search tools and AI-powered intelligence queries – have a straightforward purpose: making a fast-moving sector more understandable.
That may become one of the defining challenges of longevity’s next decade because longevity is no longer just a scientific conversation happening inside laboratories. It is becoming a capital markets story, a healthcare systems story and, increasingly, a demographic story.
Populations are aging globally. Chronic disease costs continue climbing. Healthspan (not simply lifespan) is starting to matter economically as much as medically. That shift changes the stakes entirely.
The bigger story underneath the ranking
What makes the Unfiltered Longevity 100 interesting is not simply who made the list. It is what the existence of the list signals. Longevity is moving out of its speculative adolescence, not because the science is settled; it is not. Not because the breakthroughs are guaranteed; they are not. But because enough serious people, institutions and capital now believe aging biology is worth investigating at scale.
That alone is a cultural shift. And increasingly, the conversation is becoming more specific. A few years ago, longevity discussions often drifted into vague promises about “reversing aging.” Today, the field is starting to organize itself around clearer therapeutic categories and measurable biological targets.
Phil Newman is Founder and CEO of Longevity.Technology
Newman believes one of the most important areas over the next decade will be senotherapeutics (also known as senolytics), therapies designed to clear senescent cells from the body.
“Senotherapeutics, or senolytics. These are drugs focused on clearing cellular waste as we age,” Newman said. “We accumulate damage, and senescent cells become prevalent in our bodies.”
Aging is not always about a single catastrophic breakdown; often, it is the slow accumulation of small dysfunctions that the body can no longer clean up efficiently. Senolytics aim to help restore that cleanup process. Importantly, Newman points out that science is already beginning to escape the lab and enter consumer-facing products.
“You can already see this science breaking through into consumer products, such as skincare,” he said. “They’re not therapeutics, but they’re using the science of senotherapeutics to enhance skincare regimes.”
That crossover matters because longevity is increasingly becoming visible in everyday life, not just in biotech headlines. Consumers may encounter aging science first through skincare, diagnostics or wellness products long before prescription therapeutics arrive. However, the more ambitious frontier remains deeper biological intervention.
If Newman had $10 million to invest in longevity right now, he says he would place it into partial cellular reprogramming, one of the most closely watched and controversial areas in the field.
“I’d put it into partial cellular reprogramming because it’s such a new approach to biotechnology,” he said. “We’re starting to see it work in vivo, in vitro, and now it’s beginning to move into humans.”
Again, that can sound intimidating, but the concept is easier to grasp than it first appears. Cellular reprogramming attempts to restore aged cells to a more youthful state – not unlike rebooting an aging computer system that has accumulated years of glitches and corrupted files. If successful, the implications could extend far beyond aesthetics or wellness.
“If it works, it sits at that very important longevity level six, where you’re helping people with organ-specific diseases, whether that’s liver disease, cardiovascular disease, or even neurological conditions,” Newman explained. “Then you move into the next phase, where that same technology could work across the entire body. That’s really where, depending on how you define longevity, things get interesting.”
The final line captures the strange balancing act now happening across the industry. Longevity remains full of uncertainty, unanswered questions and scientific risk, but it is also becoming more grounded, more structured and more clinically serious.
Despite that uncertainty, Newman says what encourages him most is the growing alignment now taking place across science, capital and technology.
“What makes me optimistic is the convergence I’m seeing: better geroscience pipelines, sharper investment discipline and AI-driven intelligence platforms all pointing in the same direction – away from speculation and towards scalable, real-world longevity solutions.”
The field still carries ambition bordering on audacity. But increasingly, it also carries structure, scrutiny and infrastructure. Somewhere between those forces, longevity is beginning to take shape as an early architecture of a new healthcare category.
Photograph of Phil Newman by https://ivanweiss.london/. Other photographs courtesy of Unfiltered.